BACKGROUND: Hyaluronic acid (HA) is increasingly in demand as a dermal agent for the correction of age-related soft tissue defects, such as skin laxity, loss of hydration, wrinkle formation and roughening of skin texture. IBSA Pharmaceuticals’ Profhilo® is the first BDDE-free injectable formulation of thermally-stabilized, cooperative hybrid HA complexes which efficacy has been proven both in vitro and in several independent published clinical studies.This monocentric retrospective observational study tests the efficacy and tolerability of the clinical use of Profhilo according to the specifically-developed 5-injection point Bio-Aesthetic Points (BAP) technique for facial skin bioremodeling and treatment of laxity of the malar and submalar areas.
METHODS:Ten female patients with visible signs of facial skin aging were treated with injections of Profhilo® in 3 sittings at 4-week intervals. Photographical evidence, 3D microstructure capture and quantitative data on skin hydration levels and elasticity were collected at the time of treatment and 1 month after its completion. Patients’ and doctors’ subjective evaluations of the treatment’s aesthetic result were recorded according to the GAIS scale.
RESULTS: At 1 month after treatment, photographical evidence and 3D Complexion analysis highlighted a clear reduction in wrinkle depth and smoothing of skin texture. Corneometry analysis showed a statistically significant 29% improvement in skin hydration, and cutometry analysis recorded a statistically significant 25.1% increase in skin compliance (R0) and 47.4% increase in skin elasticity. Both patient and doctor satisfaction levels were high, with average GAIS scores of 2.6 and 2.8, respectively. CONCLUSIONS: Overall the treatment was well tolerated, and no notable side effects were recorded.
(Cite this article as: Goltsova EN, Shemonaeva OA. Hybrid cooperative complexes of H-HA and L-HA (Profhilo®) and the BAP technique for facial skin bioremodeling: a clinical experience at the NEO-Clinic (Tyumen, Russia). Esperienze Dermatol 2019;21:47-53. DOI: 10.23736/S1128- 9155.19.00492-8)